Drug intelligence / Profile preview

HLX07 + carboplatin + pemetrexed

Development stage: Unknown
Lead developer: Henlius
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

HLX07 + carboplatin + pemetrexed is a combination regimen under clinical investigation for the treatment of advanced solid tumors. HLX07 is a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), developed by Henlius. It was engineered from cetuximab to reduce immunogenicity and improve affinity, aiming to inhibit tumor cell proliferation by blocking EGFR signaling pathways[1][2][3][6]. Carboplatin and pemetrexed are established chemotherapeutic agents; carboplatin is a platinum-based DNA crosslinker, while pemetrexed inhibits folate-dependent enzymes involved in nucleotide synthesis. The combination aims to leverage the targeted action of HLX07 with the cytotoxic effects of chemotherapy for enhanced antitumor efficacy[5].

Brand names: None
Other names: None

Targets

TS (Thymidylate synthase)EGFR (Epidermal growth factor receptor)DNA

Beyond the preview

Go deeper on HLX07 + carboplatin + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLX07 + carboplatin + pemetrexed.

Explore the full profile